Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H ( (HK:1558) ) has provided an announcement.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Co., Ltd. have announced the proposed pre-conditional privatization of YiChang HEC ChangJiang Pharmaceutical by way of a merger. The merger process has seen partial fulfillment of pre-conditions, with approvals from the CSRC completed, while approval from the Stock Exchange’s Listing Committee is still pending. Additionally, the long-stop date for fulfilling these conditions has been extended, indicating ongoing efforts to finalize the merger.
The most recent analyst rating on (HK:1558) stock is a Buy with a HK$13.80 price target. To see the full list of analyst forecasts on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H stock, see the HK:1558 Stock Forecast page.
More about YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products in China.
Average Trading Volume: 9,198,022
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.99B
For detailed information about 1558 stock, go to TipRanks’ Stock Analysis page.